The Evaluating Multidisciplinary Bone Marrow Failure Care in Bone Marrow Failure and Related Disorders.
NCT04819607 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2021-08-23
Summary
This is a prospective hybrid implementation-effectiveness study of a model of care for patients with bone marrow failure syndromes and inherited predisposition to haematological malignancy that includes comprehensive diagnostic genomic evaluation, multidisciplinary case review, provision of clinical care including from clinical haematologists, medical geneticists and genetic counsellors.
Conditions
- Bone Marrow Failure Syndrome
- Aplastic Anemia
Interventions
- OTHER
-
model of care
Multidisciplinary model of care for BMFS patients.
Sponsors & Collaborators
-
Peter MacCallum Cancer Centre, Australia
lead OTHER
Principal Investigators
-
Piers Blombery, MBBS(Hons) · Peter MacCallum Cancer Centre, Australia
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-06-09
- Primary Completion
- 2023-04-30
- Completion
- 2024-04-30
Countries
- Australia
Study Locations
More Related Trials
-
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
NCT02718833 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes
NCT00411905 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
NCT01083602 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma
NCT00445068 ·Status: TERMINATED ·Phase: PHASE2
-
Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma
NCT01549431 ·Status: COMPLETED ·Phase: PHASE1
-
The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)
NCT00436059 ·Status: COMPLETED ·Phase: PHASE2
-
Pethema Multiple Myeloma 2000
NCT00560053 ·Status: COMPLETED ·Phase: PHASE3
-
Anonymization of Clinical Data From Pseudonymized Databases Collected as Part of Previus Clinical Trials on Multiple Myeloma
NCT07283224 ·Status: RECRUITING
-
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
NCT02719613 ·Status: COMPLETED ·Phase: PHASE2
-
Preemptive Strike With Bortezomib in Multiple Myeloma Patients
NCT00657553 ·Status: TERMINATED ·Phase: PHASE3
-
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
NCT04817007 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
NCT03127761 ·Status: RECRUITING
-
A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma
NCT01801436 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment Optimization in Patients With Untreated Multiple Myeloma
NCT02145598 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
NCT02612779 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
NCT01478048 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
NCT02561962 ·Status: COMPLETED ·Phase: PHASE1
-
Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study
NCT00793650 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma
NCT02568943 ·Status: NO_LONGER_AVAILABLE
-
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
NCT00948922 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
NCT02159365 ·Status: COMPLETED ·Phase: PHASE2
-
An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy
NCT00216697 ·Status: COMPLETED ·Phase: PHASE2
-
Modified Bortezomib-based Combination Therapy for Multiple Myeloma
NCT02559154 ·Status: UNKNOWN ·Phase: PHASE4
-
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
NCT00461045 ·Status: COMPLETED ·Phase: PHASE2
-
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
NCT05514990 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2